Coverage
Filings
| Filing | Date |
|---|---|
| Julie Brown - External Appointment | 20 Feb 2024 |
| Director/PDMR Shareholding | 19 Feb 2024 |
| GSK completes acquisition of Aiolos Bio | 15 Feb 2024 |
| Director/PDMR Shareholding | 15 Feb 2024 |
| Director/PDMR Shareholding | 13 Feb 2024 |
| Director/PDMR Shareholding | 13 Feb 2024 |
| Director/PDMR Shareholding - Replacement | 13 Feb 2024 |
| US FDA Fast Track designation for bepirovirsen | 12 Feb 2024 |
GSK said Monday it has appointed Chief Commercial Officer Luke Miels as its next chief executive, succeeding Dame Emma Walmsley.
GSK PLC announced plans to invest $30 billion in the United States over the next five years to boost its research, development, and manufacturing capabilities.
GSK said on Monday that the U.S. Food and Drug Administration has accepted for review its application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to at-risk adults aged 18 to 49.
| Director/PDMR Shareholding |
| 12 Feb 2024 |
| Director/PDMR Shareholding | 12 Feb 2024 |
| Director/PDMR Shareholding | 12 Feb 2024 |
| GSK presents positive DREAMM-7 phase III data | 6 Feb 2024 |